X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1177) 1177
Book Review (269) 269
Publication (105) 105
Book Chapter (8) 8
Conference Proceeding (5) 5
Dissertation (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sunitinib (958) 958
index medicus (907) 907
humans (786) 786
oncology (659) 659
cancer (445) 445
female (408) 408
male (406) 406
middle aged (325) 325
tyrosine kinase inhibitor (325) 325
aged (297) 297
indoles - therapeutic use (294) 294
pyrroles - therapeutic use (290) 290
antineoplastic agents - therapeutic use (288) 288
adult (250) 250
carcinoma, renal cell - drug therapy (249) 249
metastasis (249) 249
kidney neoplasms - drug therapy (237) 237
endothelial growth-factor (230) 230
renal-cell carcinoma (220) 220
pharmacology & pharmacy (215) 215
care and treatment (213) 213
sorafenib (213) 213
animals (206) 206
renal cell carcinoma (204) 204
tumors (192) 192
treatment outcome (190) 190
indoles - adverse effects (188) 188
medicine & public health (186) 186
pyrroles - adverse effects (185) 185
indoles - administration & dosage (183) 183
antineoplastic agents (182) 182
interferon-alpha (180) 180
antimitotic agents (179) 179
pyrroles - administration & dosage (178) 178
sunitinib malate (172) 172
angiogenesis (165) 165
su11248 (162) 162
chemotherapy (160) 160
antineoplastic agents - adverse effects (159) 159
vascular endothelial growth factor (158) 158
carcinoma, renal cell (153) 153
analysis (151) 151
kidney neoplasms - pathology (146) 146
bevacizumab (145) 145
indoles - pharmacology (144) 144
pyrroles - pharmacology (144) 144
therapy (144) 144
tyrosine (142) 142
research (140) 140
drug therapy (139) 139
efficacy (135) 135
antitumor-activity (133) 133
survival (121) 121
aged, 80 and over (115) 115
phase-ii (115) 115
angiogenesis inhibitors - therapeutic use (114) 114
disease-free survival (108) 108
imatinib mesylate (108) 108
protein kinase inhibitors - therapeutic use (107) 107
carcinoma, renal cell - pathology (105) 105
mice (103) 103
antineoplastic agents - administration & dosage (99) 99
cancer research (99) 99
imatinib (99) 99
urologic and male genital diseases (99) 99
angiogenesis inhibitors (98) 98
antineoplastic agents - pharmacology (96) 96
expression (96) 96
in-vivo (94) 94
pharmacology/toxicology (94) 94
targeted therapy (94) 94
everolimus (92) 92
prognosis (91) 91
trial (90) 90
urology & nephrology (88) 88
vegf (88) 88
health aspects (87) 87
indoles - pharmacokinetics (87) 87
neoplasm metastasis (86) 86
pyrroles - pharmacokinetics (86) 86
safety (86) 86
clinical trials (85) 85
retrospective studies (85) 85
neoplasms - drug therapy (84) 84
antineoplastic combined chemotherapy protocols - therapeutic use (80) 80
gastrointestinal stromal tumors - drug therapy (79) 79
pharmacokinetics (78) 78
tyrosine kinase inhibitors (78) 78
cell line, tumor (76) 76
kinases (76) 76
hematology, oncology and palliative medicine (72) 72
hypertension (72) 72
patients (72) 72
phase-ii trial (72) 72
carcinoma (71) 71
kidney cancer (70) 70
gastrointestinal stromal tumors (69) 69
development and progression (68) 68
protein kinase inhibitors - adverse effects (68) 68
cancer therapies (67) 67
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1158) 1158
Japanese (7) 7
French (6) 6
German (5) 5
Korean (4) 4
Chinese (3) 3
Spanish (2) 2
Polish (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Annals of Oncology, ISSN 0923-7534, 9/2008, Volume 19, Issue 9, pp. 1613 - 1618
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2009, Volume 45, Issue 11, pp. 1959 - 1968
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2012, Volume 30, Issue 2, pp. 794 - 802
Background Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided... 
Medicine & Public Health | Renal cell carcinoma | 2-methoxyestradiol | Clinical trials | Sunitinib malate | Oncology | Phase II | Pharmacology/Toxicology | Antiangiogenic agent | ENDOGENOUS ESTROGEN METABOLITE | APOPTOSIS | ORAL 2-METHOXYESTRADIOL | SORAFENIB | TRIAL | INTERFERON-ALPHA | THERAPY | ONCOLOGY | PATHWAY | INHIBITS ANGIOGENESIS | PHARMACOLOGY & PHARMACY | TUMOR-GROWTH | Estradiol - analogs & derivatives | United States | Colloids | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Indoles - administration & dosage | Nanoparticles | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - metabolism | Pyrroles - administration & dosage | Treatment Failure | Aged, 80 and over | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Drug Administration Schedule | Administration, Oral | Estradiol - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Survival Analysis | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Patient outcomes | Dosage and administration | Research | Carcinoma, Renal cell | Antineoplastic agents | Drug therapy | Studies | Angiogenesis | Pharmacology | Cancer therapies | Cancer | Index Medicus
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 1/2008, Volume 134, Issue 1, pp. 51 - 57
Physiological and molecular findings indicate over-expression of HER proteins and dysregulation of neo-angiogenesis during progression of advanced prostate... 
Animal model | Sunitinib | Medicine & Public Health | Hematology | Docetaxel | Internal Medicine | Cancer Research | Oncology | Drug combinations | Cetuximab | Prostate cancer | sunitinib | NUDE-MICE | GROWTH-FACTOR-RECEPTOR | cetuximab | COMBINATION | CHEMOTHERAPY | drug combinations | prostate cancer | ONCOLOGY | docetaxel | IN-VIVO | ENDOTHELIAL-CELLS | TYROSINE KINASE INHIBITOR | animal model | PHASE-I | EXPRESSION | PROGRESSION | Cell Proliferation | Humans | Neoplasms, Hormone-Dependent - secondary | Male | Gene Expression Profiling | RNA, Messenger - metabolism | Indoles - administration & dosage | Antibodies, Monoclonal, Humanized | Pyrroles - administration & dosage | Biomarkers, Tumor - metabolism | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | RNA, Messenger - genetics | Tumor Cells, Cultured - drug effects | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Prostate-Specific Antigen - blood | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Biomarkers, Tumor - genetics | Mice | Neoplasms, Hormone-Dependent - drug therapy | Analysis | Physiological aspects | Development and progression | Angiogenesis inhibitors | Hormones | Health aspects | Index Medicus
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 7/2011, Volume 103, Issue 3, pp. 491 - 501
Journal Article
AAPS PharmSciTech, ISSN 1530-9932, 1/2018, Volume 19, Issue 1, pp. 123 - 133
Journal Article
Microchemical Journal, ISSN 0026-265X, 11/2019, Volume 150, p. 104089
Effective transportation of drugs in human body plays a crucial role in treatment procedure. Bovine serum albumin (BSA) is one of the most important drug... 
Sunitinib malate | BSA | SPR | Kinetic | Molecular docking | Thermodynamic
Journal Article
Journal Article